CMS declares no change in payment policies for ESAs
This article was originally published in Scrip
In issuing its final decree, the US Centers for Medicare & Medicaid Services (CMS) stuck with the preliminary decision it issued in March to not impose payment restrictions on erythropoiesis stimulating agents (ESAs), like Amgen's Epogen (epoetin alfa) and Aranesp (darbepoetin alfa) and Centocor Ortho Biotech's Procrit's (epoetin alfa), for use in managing anemia in dialysis or non-dialysis chronic kidney disease (CKD) patients.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.